Reuters Market Eye - Shares in Lupin Ltd (NSI:LUPIN.NS - News) gain 3.2 percent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the U.S. regulator.
A Lupin spokesman was not immediately reachable for comment.
(Reporting by Abhishek Vishnoi)
- Health Care Industry
- Lupin Ltd